5 resultat
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the United States national phase of International Application No. PCT/IB2016/055565 filed Sep. 17, 2016, and claims priority to Indian Patent Application No. 918/MUM/2015 filed Sep. 19, 2015, the disclosures of which are hereby incorporated
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of pulmonary, cardiac, and inflammation disorders. In particular, it relates to methods for treatment of these disorders and screening for therapeutic agents to treat these disorders.
BACKGROUND OF THE INVENTION
Hypoxia-induced
FIELD
Provided herein are aldehyde compounds for use in treating diseases such as pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a deadly lung
FIELD
Provided herein are aldehyde compounds for use in treating diseases such as pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a deadly lung
FIELD
Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde (hereinafter "Compound 1" or "voxelotor"), formulations and compositions of Compound 1, and processes of manufacturing such tablets. The present